Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (5408)	1/12/2002 12:33:53 PM
From: russwinter	Read Replies (1) of 52153

<cancer field.> Fallout from this seems to be leading to quite compressed valuations. Note MAXM with a 148 m market cap, and working capital (no debt) of 146 m. Basically a net-net with plant and their phase II and III various trials on Ceplene thrown in for free. One product company, but are the odds against this pipeline that bleak? I thought observers were pretty excited about some of the results? CEGE in the high teens would be similar.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next